Intrathecal drug administration is typically used for the treatment of cancer-related chronic pain or muscle spasticity. Explore the challenges associated with repeatable delivery by intrathecal injection. Topics include the impact of anatomical differences of drug delivery, the impact of CSF flow dynamics on drug delivery and potential solutions for variability between subjects in intrathecal drug delivery. Watch now: https://hubs.ly/Q02H7Cfw0 #imagingCRO
Invicro
Biotechnology Research
Needham, MA 13,422 followers
A global CRO offering imaging biomarkers, core lab services, analytics & software solutions to pharma/biotech sponsors.
About us
Headquartered in Needham, MA, Invicro was founded in 2008 with the mission of improving the role and function of imaging in translational drug discovery and development across all therapeutic areas. Today, Invicro’s multi-disciplinary team provides solutions to pharmaceutical and biotech companies across all stages of the drug development pipeline (Phase 0-IV), all imaging modalities and all therapeutic areas, including neurology, oncology, and systemic and rare diseases. Invicro’s quantitative biomarker services, advanced analytics and AI tools, and clinical operational services are backed by Invicro’s industry-leading software informatics platforms, VivoQuant® and iPACS®, as well as their pioneering IQ-Analytics Platform, which includes AmyloidIQ, TauIQ and DaTIQ.
- Website
-
http://www.invicro.com/
External link for Invicro
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Needham, MA
- Type
- Privately Held
- Founded
- 2008
- Specialties
- software development, advanced statistics, automated reporting, electronic record keeping, consulting, MRI, CT, SPECT, PET, Optical, Ultra Sound, iPACS, VivoQuant, clinical research, fMRI, BLI imaging, and CRO
Locations
-
Primary
Get directions
Invicro, LLC.
119 Fourth Avenue
Needham, MA 02494, US
-
Get directions
N/A
London, GB
-
Get directions
60 Temple Street
New Haven, CT 06510, US
Employees at Invicro
Updates
-
The vast majority of the RLT companies conducting clinical translation have relied on Invicro’s scientific collaboration to bring their molecules to an IND. Meet with Invicro's @SeanCarlin at #TRPSummit to discover how our pioneering approach to radioligand therapy development accelerates the path to human trials and seamlessly integrates with the existing clinical #RLT ecosystem: https://hubs.ly/Q02GWNjn0 #radiopharmaceuticals #theranostics #NuclearMedicine #MolecularImaging
-
-
Whether you’re dealing with complex medical imaging challenges or managing diverse datasets, Invicro has you covered. Our Advanced Special Projects (ASP) team offers bespoke AI/ML solutions, and our software image analysis (SWIA) offerings provide tailored solutions designed to meet specific analytical needs using your existing datasets. Get in touch with our team to discover how our integrated approach can elevate your research: https://hubs.ly/Q02GKlX90
-
-
We look forward to seeing you during #AAIC24 in Philadelphia from July 28 to August 1. CALYX/Invicro have been pioneers in #AlzheimersResearch for over two decades, providing support in the majority of the most critical #AlzheimersTrials over the past ten years. Stop by booth #921 and learn how we empower #Alzheimer's disease research with our extensive experience across preclinical, early-phase, and late-phase clinical studies. Trust your pivotal trials with our scientific and operational experts, who can proactively address challenges before they arise. Let's connect: https://hubs.ly/Q02GjdVW0 #AAIC2024
-
-
Invicro is thrilled to see a significant step forward with CMS's proposed changes to the Hospital Outpatient Prospective Payment System (OPPS) for 2025! For too long, diagnostic radiopharmaceuticals have been bundled into overall payment systems, often leading to underfunding for these critical tools. By recognizing the unique value and cost of advanced diagnostics, CMS is paving the way for greater accessibility and utilization of cutting-edge nuclear medicine procedures. This change is a monumental leap forward for patients who depend on accurate, timely diagnoses. #radiopharmaceuticals #RLT
There's a new proposed rule that unbundles diagnostic radiopharmaceuticals from the current packaged payment system that classifies them as "supplies." The new rule will prevent CMS from overpaying for low-cost diagnostic radiopharmaceuticals and give patients access to a more precise generation of imaging agents. SNMMI will be submitting a comment in support of the CMS rule and is celebrating this win for patients! Learn more below and on our website: https://lnkd.in/dkPjWqXa
-
Did you know that reproducible and time-efficient criteria based on FDG-PET imaging have led to improved clinical outcomes in the development of new cancer therapies for FDG-avid lymphoma? Join a panel of experts as they discuss the evolution of imaging-based response criteria for lymphomas, challenges in developing a standardized operational reader workflow for clinical trials, and operational recommendations for radiologists using lymphoma response assessment criteria. Don't miss out on this informative discussion! https://hubs.ly/Q02DZzdG0 #PET #lymphoma #oncology #imagingCRO
-
-
We’re excited to attend the 3rd Annual Targeted Radiopharmaceuticals (TRP) Summit on July 30-August 1 in San Diego! While radioligand therapies have gained significant traction in recent years, Invicro has been dedicated to nuclear medicine for over two decades, leading the forefront of the radiopharmaceutical boom. Your preclinical and clinical trials need Invicro as your scientific and operational collaborator. Let’s meet to discuss your RLT programs: https://hubs.ly/Q02G0_PV0 #TRPsummit #theranostics #radiopharmaceuticals #nuclearmedicine #molecularimaging
-
-
Invicro's Software and Image Analysis (SWIA) team excels in managing a variety of imaging formats and applications to enhance your understanding of imaging biomarkers. Our customized approach seamlessly integrates with your data to provide insightful, precise analyses. Ready to elevate your research? Get in touch: https://hubs.ly/Q02D1cp10
-
-
The development and optimization of novel radioligands for drug development applications is critical to move new compounds from bench to bedside. Join Lisa Wells, PhD as she provides an overview of a typical study design for the development of a suitable PET radioligand for a novel target in CNS disease models. She explains the importance of determining target expression in the tissue(s) of interest and candidate ligand characteristics prior to in vivo imaging and explores how data is analyzed in preclinical animal models, non-human primates and human subjects. https://bit.ly/4cIu4ch #PET #SPECT #CNS #radioligand
-